Literature DB >> 16723549

Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.

Tyree H Kiser1, Dorie W Hoody, Marilee D Obritsch, Colleen O Wegzyn, Paulus C Bauling, Douglas N Fish.   

Abstract

Levofloxacin pharmacokinetics were studied in 11 patients with severe burn injuries. Patients (values are means +/- standard deviations; age, 41 +/- 17 years; weight, 81 +/- 12 kg; creatinine clearance, 114 +/- 40 ml/min) received intravenous levofloxacin at 750 mg (n = 10 patients) or 500 mg (n = one patient) once daily. Blood samples were collected on day 1 of levofloxacin therapy; eight patients were studied again on days 4 to 6. The pharmacodynamic probability of target attainment (PTA) was evaluated by Monte Carlo simulation. Mean systemic clearance, half-life, and area under the concentration-time curve over 24 h after levofloxacin at 750 mg were 9.0 +/- 3.2 liters/h, 7.8 +/- 1.6 h, and 93 +/- 31 mg . h/liter, respectively. There were no differences in pharmacokinetic parameters between day 1 and day 4; however, large intrapatient and interpatient variability was observed. Levofloxacin pharmacokinetics in burned patients were similar to those reported in other critically ill populations. Levofloxacin at 750 mg achieved >90% PTA for gram-negative and gram-positive pathogens with MICs of < or =0.5 microg/ml and MICs of < or =1 microg/ml, respectively. However, satisfactory PTA was not obtained with less-susceptible gram-negative organisms with MICs of 1 microg/ml or any organism with a MIC of > or =2 microg/ml. The results of this study indicate that levofloxacin should be administered at 750 mg/day for treatment of systemic infections in severely burned patients. However, even 750 mg/day may be inadequate for gram-negative organisms with MICs of 1 to 2 microg/ml even though they are defined as susceptible. Alternative antibiotics or treatment strategies should be considered for infections due to these pathogens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723549      PMCID: PMC1479115          DOI: 10.1128/AAC.01466-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

Review 1.  Pathophysiology and pharmacokinetics following burn injury.

Authors:  P L Bonate
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urine.

Authors:  F A Wong; S J Juzwin; S C Flor
Journal:  J Pharm Biomed Anal       Date:  1997-03       Impact factor: 3.935

3.  Altered neutrophil functions in patients with large burns.

Authors:  R Bjerknes; H Vindenes; O D Laerum
Journal:  Blood Cells       Date:  1990

4.  Ciprofloxacin pharmacokinetics in burn patients.

Authors:  J C Garrelts; G Jost; S F Kowalsky; G J Krol; J T Lettieri
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection.

Authors:  P Bourget; A Lesne-Hulin; R Le Reveillé; H Le Bever; H Carsin
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

6.  Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.

Authors:  S L Preston; G L Drusano; A L Berman; C L Fowler; A T Chow; B Dornseif; V Reichl; J Natarajan; M Corrado
Journal:  JAMA       Date:  1998-01-14       Impact factor: 56.272

7.  Inhibition of leukocyte-endothelial adherence following thermal injury.

Authors:  W Mileski; D Borgstrom; E Lightfoot; R Rothlein; R Faanes; P Lipsky; C Baxter
Journal:  J Surg Res       Date:  1992-04       Impact factor: 2.192

8.  Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.

Authors:  K J Madaras-Kelly; B E Ostergaard; L B Hovde; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 9.  Current treatment of severely burned patients.

Authors:  T T Nguyen; D A Gilpin; N A Meyer; D N Herndon
Journal:  Ann Surg       Date:  1996-01       Impact factor: 12.969

10.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Authors:  A Forrest; D E Nix; C H Ballow; T F Goss; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  8 in total

1.  Carbapenem-Containing Combination Antibiotic Therapy against Carbapenem-Resistant Uropathogenic Enterobacteriaceae.

Authors:  Maria Loose; Isabell Link; Kurt G Naber; Florian M E Wagenlehner
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

2.  Mutant prevention concentrations of levofloxacin, pazufloxacin and ciprofloxacin for A. baumannii and mutations in gyrA and parC genes.

Authors:  Chengchun Sun; Junwen Hao; Meiqin Dou; Yanwen Gong
Journal:  J Antibiot (Tokyo)       Date:  2014-11-05       Impact factor: 2.649

3.  Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin.

Authors:  Robyn Defife; Marc H Scheetz; Joe M Feinglass; Michael J Postelnick; Kimberly K Scarsi
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 4.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  [Not Available].

Authors:  R Le Floch; E Naux; J F Arnould
Journal:  Ann Burns Fire Disasters       Date:  2015-06-30

6.  Does Critical Illness Change Levofloxacin Pharmacokinetics?

Authors:  Jason A Roberts; Menino Osbert Cotta; Piergiorgio Cojutti; Manuela Lugano; Giorgio Della Rocca; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

7.  Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid Fever.

Authors:  Muhammad Usman; Muhammad Ashraf; Muhammad Imran Khokhar; Bilal Ashiq; Muhammad Irfan Masood; Shehryar Afzal; Ovais Omer; Mohsin Ali; M Imran Qadir
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

8.  Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization.

Authors:  G Cao; J Zhang; X Wu; J Yu; Y Chen; X Ye; D Zhu; Y Zhang; B Guo; Y Shi
Journal:  J Clin Pharm Ther       Date:  2013-05-24       Impact factor: 2.512

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.